A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes
Patients with DLBCL with bulky disease and/or those who fail to achieve complete response benefit from the addition of radiotherapy (RT). We aim to review the outcome, as well as determine the impact of cell-of-origin, on patients undergoing consolidative RT.
Patients with DLBCL treated with radical intent consolidative radiotherapy were included. Clinical, pathological and treatment characteristics were extracted from electronic medical records. Survival outcomes and factors which predict for disease-free survival (DFS) were analysed.
Seventy-four patients were included in this analysis. The median follow up was 3 years (0.7 – 16 year). Fifty eight percent of patients had stage I-II disease, and 61% received at least 6 cycles of chemotherapy. Cell-of-origin was discernible in 60% of patients, and approximately half were classified as Germinal centre origin. The 5-year overall survival (OS) of this group was excellent at 92% (median survival not reached). The 5-year DFS was 73% (95% CI 57 – 83%). Seven percent (n = 5) of patients experienced local recurrence at a median time of 6 months. Failure to achieve complete response post RT and/or initial bulky disease are significant predictors of inferior DFS. There was no association between cell-of-origin and DFS or OS.
The outcome of patients who received radiotherapy as consolidation is excellent. Patients who fail to achieve complete response after radiotherapy had poorer outcomes. Despite using radiotherapy, presence of bulky disease remains a significant predictor of disease recurrence. A well-designed randomised controlled trial, comparing treatment with chemotherapy alone, would be useful to determine the additional benefit of radiotherapy.